Genomic Health (NASDAQ:GHDX) Rating Increased to Buy at ValuEngine

ValuEngine upgraded shares of Genomic Health (NASDAQ:GHDX) from a hold rating to a buy rating in a report released on Saturday morning, ValuEngine reports.

A number of other equities analysts have also recently issued reports on the company. Canaccord Genuity increased their target price on ServiceNow from $285.00 to $300.00 and gave the stock a buy rating in a report on Wednesday, May 8th. Deutsche Bank set a $18.00 target price on Commercial Metals and gave the stock a buy rating in a report on Thursday, May 30th. BidaskClub cut Weyco Group from a sell rating to a strong sell rating in a report on Saturday, July 13th. Zacks Investment Research lowered shares of Hallmark Financial Services from a buy rating to a hold rating in a research note on Thursday, July 25th. Finally, Piper Jaffray Companies reaffirmed a buy rating on shares of Beigene in a research note on Thursday, June 20th. Eleven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $64.56.

GHDX stock opened at $74.00 on Friday. The stock’s 50-day moving average is $57.59. The company has a market cap of $2.74 billion, a PE ratio of 70.48 and a beta of 1.07. The company has a quick ratio of 5.67, a current ratio of 5.67 and a debt-to-equity ratio of 0.19. Genomic Health has a 1 year low of $50.77 and a 1 year high of $92.18.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings results on Monday, July 29th. The medical research company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.07. The business had revenue of $114.14 million for the quarter, compared to analyst estimates of $110.78 million. Genomic Health had a return on equity of 18.70% and a net margin of 10.35%. The company’s quarterly revenue was up 19.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.23 earnings per share. As a group, research analysts forecast that Genomic Health will post 1.46 EPS for the current year.

In other Genomic Health news, insider Kim Mceachron sold 5,335 shares of the firm’s stock in a transaction on Friday, July 5th. The stock was sold at an average price of $60.01, for a total transaction of $320,153.35. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Steven Shak sold 50,000 shares of the firm’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $51.38, for a total value of $2,569,000.00. The disclosure for this sale can be found here. Insiders sold 152,025 shares of company stock worth $8,175,806 in the last 90 days. Corporate insiders own 31.30% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. lifted its position in shares of Genomic Health by 166.0% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 493 shares in the last quarter. Manchester Capital Management LLC bought a new position in shares of Genomic Health during the first quarter valued at about $56,000. Pearl River Capital LLC bought a new position in shares of Genomic Health during the first quarter valued at about $70,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Genomic Health by 29.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,923 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 441 shares in the last quarter. Finally, Advisor Group Inc. lifted its position in shares of Genomic Health by 34.9% during the 4th quarter. Advisor Group Inc. now owns 1,995 shares of the medical research company’s stock worth $129,000 after buying an additional 516 shares in the last quarter. 95.06% of the stock is currently owned by institutional investors.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Featured Article: Cost of Goods Sold (COGS)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.